Cyclosporin A treatment of 83 children with nephrotic syndrome of different pathological types

OBJECTIVE: To evaluate the efficacy of cyclosporin A (CyA) therapy in 83 children with nephrotic syndrome of different pathological types

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 41(2003), 11 vom: 29. Nov., Seite 813-6
1. Verfasser: Xia, Zheng-kun (VerfasserIn)
Weitere Verfasser: Liu, Guang-ling, Gao, Yuan-fu, Fu, Jie, Fu, Yuan-feng, Zhang, Lian-feng, Fan, Zhong-min
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2003
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:Clinical Trial Comparative Study English Abstract Journal Article Immunosuppressive Agents Cyclosporine 83HN0GTJ6D
LEADER 01000caa a22002652 4500
001 NLM144361566
003 DE-627
005 20250205063515.0
007 tu
008 231223s2003 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0481.xml 
035 |a (DE-627)NLM144361566 
035 |a (NLM)14728885 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Xia, Zheng-kun  |e verfasserin  |4 aut 
245 1 0 |a Cyclosporin A treatment of 83 children with nephrotic syndrome of different pathological types 
264 1 |c 2003 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 16.06.2004 
500 |a Date Revised 07.06.2016 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: To evaluate the efficacy of cyclosporin A (CyA) therapy in 83 children with nephrotic syndrome of different pathological types 
520 |a METHODS: Eighty-three children enrolled in this study were all hospitalized children with idiopathic nephrotic syndrome, aged 3 to 14 yrs (average 8.3 yrs) and included 52 males and 31 females. There were 35 cases with steroid-dependent, 17 with steroid resistant and 26 with frequent relapses. CyA was given to each patient with dosage of 5 mg/(kg.d) during the corticosteroid was diminished. The renwal biopsy was performed in all patients before the administration of CyA. The duration of CyA therapy lasted for about 3 to 6 months. The plasma concentration of CyA was monitored 
520 |a RESULTS: Eighty-three children with nephrotic syndrome of different pathological types were treated with CyA, including 42 cases of minimal change nephrotic syndrome (MCNS), 31 cases of mesangioproliferative glomerulonephritis (MsPGN), 5 cases of membranoproliferative glomerulonephritis (MPGN) and 4 cases of focal segmental glomerular sclerosis (FSGS). All the 83 patients tolerated well to the CyA treatment. Forty-five cases got complete remission, 23 partial remission, 15 cases no change after one month treatment with CyA in the hospital. The overall response rate was 82%. Patients with different renal pathological types showed different responses. Among them, MCNS and MsPGN exhibited the best response rates of 86% and 84%, respectively; MPGN cases showed a lower response rate and FSGS cases showed the lowest rate. The response time was 7 to 45 days. The blood concentration of CyA was monitored for 1 week and 2 weeks after the drug was given. The effective drug concentration was maintained at 100 to 200 microg/L, and the course lasted for 3 to 6 months. During the follow-up of 83 cases, in 17 of 68 cases the disease relapsed when therapy was tapered or discontinued. The relapse rate was 25%. The results indicated that CyA would be effective to the relapsed cases. The serum creatinine increased temporarily after administration of CyA in 5 cases, N-acetyl-beta-D-glucosaminidase (NAG) in 8 cases and eventually reached the normal range after the adjustment of dosage. The side effects included anorexia, nausea, vomiting and so on 
520 |a CONCLUSION: CyA is one of the effective substitutes for the treatment of nephrotic syndrome, especially for the cases with MCNS and MsPGN. And CyA could control refractory nephrotic syndrome effectively and rapidly. The clinical effect was related to the blood concentration of CyA and pathological types 
650 4 |a Clinical Trial 
650 4 |a Comparative Study 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Cyclosporine  |2 NLM 
650 7 |a 83HN0GTJ6D  |2 NLM 
700 1 |a Liu, Guang-ling  |e verfasserin  |4 aut 
700 1 |a Gao, Yuan-fu  |e verfasserin  |4 aut 
700 1 |a Fu, Jie  |e verfasserin  |4 aut 
700 1 |a Fu, Yuan-feng  |e verfasserin  |4 aut 
700 1 |a Zhang, Lian-feng  |e verfasserin  |4 aut 
700 1 |a Fan, Zhong-min  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 41(2003), 11 vom: 29. Nov., Seite 813-6  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:41  |g year:2003  |g number:11  |g day:29  |g month:11  |g pages:813-6 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 41  |j 2003  |e 11  |b 29  |c 11  |h 813-6